20 funding opportunities are listed in this category
International Rett Syndrome Foundation HeART Award (Help Accelerate Rett Therapeutics)
Goal: To provide seed funding for early stage drug discovery and development efforts.Funding: The program provides funding in amounts ranging from $25,000-$50,000 for one year with a high likelihood of follow-on funding for successful programs.HeART Award Timeline
Cycle 1 LOIS due: March 26, 2010Applications due: April 26, 2010
Cycle 2
LOIs due: August 16, 2010Applications due: September 30, 2010
International Rett Syndrome Foundation 4600 Devitt DriveCincinnati OH 45246Telephone: 1-800-818-7388Fax: 1-513-874-2520
American Society of Hematology Scholar Awards
The ASH Scholar Awards are designed to support hematologists who have chosen a career in research by providing partial salary or other support during that critical period required for completion of training and achievement of status as an independent investigator. Eligibility Criteria (as of August 26, 2010)To be eligible for the Junior Faculty Scholar Award (either basic or clinical/translational research), applicants must be within the first three years of their initial faculty appointment as Assistant Professor at the time of application.To be eligible for the Fellow Scholar Award (either basic or clinical/translational research), applicants must have more than two years, but less than five years postdoctoral research training at the time of application. Applicants who are fellows must have completed their ACGME clinical year plus two full years (but no more than five) of postdoctoral research at the time of application.In addition to fellows, instructors, lecturers, and research associates should apply in the fellow category. The five-year maximum for postdoctoral research training also applies to these individuals. Applicants with these job titles are not yet eligible for the Junior Faculty Award.All Applicants: * Applicants must be an ASH member or have a pending application for membership. * Applicants must work in a U.S. or Canadian institution (such as a medical school, hospital, or research institute). An institution qualifies if it independently receives and administers grants and contracts from the National Institutes of Health. * Only one application per laboratory should be submitted per category (basic research fellow, basic research junior faculty, clinical/translational research fellow, and clinical/translational research junior faculty) for this competition. * Employees of the PHS at the NIH are not eligible for these awards as their salaries for research are covered under the terms of their employment. * Individuals with R01 grants or equivilant grants at the time of application are not eligible for these awards. Individuals with K awards from the NIH are eligible to apply. * At least 75 percent of the applicant’s full-time professional effort must be devoted to research.Application ProcessASH requires applicants to submit a letter of intent by May 1, 2010, in order to be eligible to submit a full proposal in August. The letter of intent should include the following: * Cover letter signed by applicant on institution letterhead (include mailing address, phone number, and e-mail address) * Abstract of proposed project, including title (please do not exceed 350 words) * Applicant's curriculum vitae * Identify which award category you plan to apply for: o Basic Research Fellow o Basic Research Junior Faculty o Clinical/Translational Research Fellow o Clinical/Translational Research Junior FacultyPlease e-mail your letter of intent to awards@hematology.org.ASH will perform a preliminary review of these materials to confirm eligibility and the appropriateness of the research category applied to. If additional information is required, ASH staff will contact you prior to June.The full ASH Scholar Award applications will be available in early June only for those individuals who successfully submit a letter of intent by the deadline and are confirmed to be eligible.Acceptance PolicyAnyone meeting the eligibility requirements set forth above can submit an application. The review of the scholar award applications is based solely on the scientific merit and quality of the applicant. However, in fairness to programmatic balance, no more than two awards will be granted per category (basic research fellow, basic research junior faculty, clinical/translational fellow, clinical/translational junior faculty) per medical school. For this purpose, ASH defines medical school so that it encompasses all sub-institutions (e.g., University of Washington would include the Fred Hutchinson Cancer Research Center, Children’s Hospital, etc.).Research SupportedBasic Research: ASH considers basic research to include a broad spectrum of studies on genes, proteins, lipids, carbohydrates, biochemical and signaling pathways, receptors, cells and animals, as well as samples obtained from humans, all of which are designed to further our understanding of the blood, bone marrow, and related organs or the pathogenesis of blood disorders. The emphasis for grants in this category should be on the discovery of new knowledge in a traditional laboratory setting.Clinical/Translational Research: ASH considers clinical/translational research to include translational research, patient-oriented research, and outcomes-based research. ASH emphasizes that clinical/translational research must involve substantial interaction with patients. * Translational Research For the purposes of the ASH Scholar Awards program, translational research means using knowledge of human biology to develop and test the feasibility of relevant interventions in humans and/or determine the biological basis for observations made in individuals with hematologic conditions or in populations at risk. Translational research should be founded on and directly connected to some aspect of human biology and may encompass any form of cellular, molecular, structural, biochemical, genetic, or other appropriate experimental approach. The proposal should address clinical applications – not just test development – although the development of novel instrumentation of value to hematology is clearly within the scope of the application.
* Patient-Oriented Research For the purposes of the ASH Scholar Awards program, patient-oriented research is defined as research conducted with human subjects and involves an investigator directly interacting with human subjects. Categories of patient-oriented research include: 1) mechanisms of human disease, 2) therapeutic interventions, 3) clinical trials, and 4) development of new technologies.
* Outcomes-Based Research ASH strongly encourages applications in outcomes-based research. Options for outcomes-based research include: 1) a decision-analysis or cost-effectiveness analysis of a relevant topic within hematology, 2) survey-based research investigating practice patterns, access to care, quality of care, clinical outcomes, or quality of life among patients with hematologic conditions, 3) retrospective analyses of large administrative databases (e.g., CMS, a large insurer, SEER) that may enlighten health care policy decisions related to hematologic disease, and 4) large scale epidemiologic or genetic epidemiologic studies that define the incidence, prevalence, prognosis, and natural history or the effects of therapy of blood disorders.Applications that fall within any of the categories discussed above are encouraged.SupportAwards are limited to a maximum of $100,000 for fellow scholars and $150,000 for junior faculty scholars over a two- to three-year period, with an annual maximum of $50,000 for fellows and $75,000 for junior faculty. Up to 15 percent of the award can be (but is not required to be) used for benefits, including medical and dental insurance, life insurance, and retirement benefits.All awards are activated on July 1 of the following year. The applicant has the option of concluding the award on June 30, two or three years after activation. All award payments are made on a quarterly basis – the amount depends on whether the award is being spread over two or three years. Payments are made to the appropriate financial officer of the institution as indicated on the proposed budget within the full application.General TimelineLetter of intent due Saturday, May 1, 2010Application available for those who successfully submit a LOI by the deadline June 2010Full proposal due Thursday, August 26, 2010Notification of awards Mid-NovemberActivation of award July 1, 2011
For more information about the ASH Scholar Awards program, please contact Elisa Shea, ASH Awards Manager, by e-mail or by phone at 202-776-0544.
American Society of Hematology2021 L Street NW, Suite 900Washington, DC 20036 Phone 202-776-0544 | Fax 202-776-0545
American Society of Hematology Mentor Award
Mentorship is one of the most important determinants of a successful career in hematology, yet it is often a component of career development that, while prized by recipients, is rarely rewarded. In recognition of the value the Society places on mentorship, the ASH Mentor Award was created to reward outstanding mentors in the hematology community. Superb mentors from any of the different branches of hematology are eligible for this award, including adult or pediatric hematologists; academic or community practitioners; basic, clinical, or translational researchers; hematopathologists; transfusion medicine specialists; and individuals working in industry or government. It is anticipated that awardees will have had a sustained career commitment to mentoring, a significant positive impact on their mentees' careers, and through their mentees have advanced research and patient care in the field of hematology.Each year one award in the amount of $5,000 and a plaque will be granted to an outstanding mentor in the basic sciences and one to an outstanding clinical investigator mentor. (The ASH Mentor Award Study Section reserves the right to not grant awards if no suitable nominations have been submitted.)
Award CriteriaThis award is based on the training experiences and success of the nominee’s mentees, not the mentor’s personal career achievements. For the purpose of this award, mentoring is defined as the process of guiding, supporting, and promoting the training and career development of others. The key roles of a mentor include, but are not limited to providing: * Intellectual growth and development * Career development * Professional guidance * Advocacy * Positive role modelingEligibility Criteria
Inclusion 1. All nominees and nominators must be members of ASH. 2. Nominees of all nationalities and all countries of residence are eligible; however, all application materials must be submitted in English. 3. Nominees may include adult or pediatric hematologists; academic or community practitioners; basic, clinical, or translational researchers; hematopathologists; transfusion medicine specialists; and individuals working in industry or government. 4. Nominees should have a sustained record of mentoring over time. 5. Nominators must be a mentee of the nominee, or colleagues who have personal knowledge of the nominee’s mentoring efforts. 6. Mentees should be actively involved in research, teaching, mentoring, or other leadership activities. 7. The nominator, primary, and secondary mentee must be three individuals.Exclusion 1. Prior recipients of the ASH Mentor Award are ineligible for future awards. 2. Current members of the ASH Executive Committee, the ASH Awards Committee, or the ASH Mentor Award Study Section are ineligible. 3. Self-nominations and posthumous nominations will not be accepted. 4. Recipients of the William Dameshek Prize, Henry M. Stratton Medal, and E. Donnall Thomas Lecture and Prize are ineligible for the year they receive the award.Nomination PackagesNomination packages must be submitted by May 4, 2010, to:ASH Training ManagerASH Mentor Award2021 L Street, NW, Suite 900Washington, DC 20036Nomination packages must include the following information: 1. The completed nomination form. 2. The nominee's curriculum vitae. 3. Three letters of recommendation. * A letter written by the nominator that summarizes the nominee's impact on the training/careers of his/her mentees. * Two letters written by the primary and secondary mentee (can be a former or current mentee) who can each provide a first-hand account of how the nominee influenced his or her career. Academic, clinical, and educational, achievements on the part of the mentee will all be considered important. These mentees must be willing to complete a structured telephone interview about the nominee's mentoring capacity. * Optional: Up to three additional letters of support from junior and senior faculty will be accepted, but are not required. Ideally, at least one letter should be written by a mentee who can provide a first-hand account of how the nominee influenced his or her career. Academic, clinical, educational, and regulatory achievements on the part of the mentee will all be considered as important.It is suggested that the nominees participate in the process of assembling the nomination package, since their mentoring achievements may have spanned many years, beyond the experience of individual mentees.Nomination and Selection ProcessNominations may be made by any member of ASH, based on either having been mentored by the nominee or by personal observation of mentoring provided to others by the nominee. Nominators may be mentees of the nominee or colleagues who have personal knowledge of the nominee's mentoring efforts.The ASH Mentor Award Study Section, which reviews nomination packages, includes, but is not limited to, four members from the ASH Trainee Council, one member from the ASH Educational Affairs Committee, one member from the ASH Awards Committee, one member from the ASH Committee on Practice, and one member from the ASH Committee on Training Programs.Nomination packages will be forwarded to the Mentor Award Study Section for review. The selection process has a quantitative and a qualitative phase. During the initial quantitative phase, nomination packages are reviewed and scored by the members of the Study Section on a mentoring score card. Several members of the Study Section review each nomination package.Nominations are scored based on the Award Criteria and the overall strength of the nomination package. The Study Section meets in June to review scores and decide on four to six finalists (broken out evenly in each of the two categories) to continue on to the qualitative component of the selection process.During the qualitative phase of the selection process, the nominator and the two mentees are contacted for each finalist for a focused telephone interview. Interviews are conducted by a professional interviewer and are based on the "semi-structured interview" technique of qualitative research. The interviews explore the mentoring strengths and track-record of the nominee. Focused interview transcripts are prepared and forwarded to members of the Study Section by August. Final selections will be based on a consensus of the entire Study Section during a conference call that takes place in mid-August. The Study Section will encourage nominators of highly ranked, but unsuccessful, nominees to resubmit their application in subsequent years. Final selections are sent to the ASH Awards Committee and the ASH Executive Committee for final approval by the end of August. Awardees are notified in September.Assessing the Selection ProcessThe selection criteria and evaluation tools were conceived in an effort to allow the Study Section a way to reach consensus, in a well-informed manner, about individuals who have consistently exemplified outstanding mentorship skills. Many of these skills are not easily assessed by academic rank or curriculum vitae. It is expected that awardees have outstanding academic records, but the aim of this selection process is to specifically address mentoring skills. To determine the utility and validity of the selection process, some nominees, nominators, referees, and awards committee members are asked to evaluate the nomination, selection, and award processes. These surveys are sent out and collated by ASH staff. Results are then reported back to the ASH Mentor Award Study Section and the appropriate procedures are modified accordingly.
2010 Selection Process Timeline
Nomination packages due. May 4, 2010
Study section to meet to review scores and decided on four to six finalists (broken out evenly in each category). June 2010
Focused interview transcripts will be prepared and forwarded to members of the ASH Mentor Award Study Section for review. August 2010
Study Section meets in a conference call to discuss final selections. August 2010
Final selections will be sent to the ASH Awards Committee and the ASH Executive Committee for final approval. August 2010
Winners notified. September 2010
Questions?Questions about the ASH Mentor Award may be directed to training@hematology.org.
2010 Clinical Translational Research Career Development Awards in Pediatric Cancer
The Larry & Helen Hoag Foundation are currently accepting grant applications for the 2010 Clinical Translational Research Career Development Awards in Pediatric Cancer.Recipients will receive a maximum of $105,000 ($100,000 direct costs and $5,000 for institutional overhead expenses).
The purpose of the Clinical Translational Research Career Development Award in Pediatric Cancer is to support the development of outstanding clinician and translational investigators in pediatric cancer research. This mechanism provides support for specialized study by pediatric oncologists committed to a career in translational laboratory and clinical-based research. Candidates must have the potential to develop into independent investigators. The Award supports a three-year mentored research experience that integrates didactic studies with laboratory and clinically based research. The proposed research must have direct relevance to pediatric cancer, and the program must provide the experienced mentorship necessary to optimize the potential for the trainee to become a well-trained independent researcher. Basic eligibility criteria consists of the following: * Candidate must have a full-time faculty appointment at a U.S. Medical Institution or University and must be within 5 years of that appointment at the time of application. * Candidate must have either an M.D. or M.D/PhD degree. * Candidate must be sub-board eligible or certified in Pediatric Hematology-Oncology. * Applicants on a J-1 training visa are ineligible.Applications will be accepted on or before April 1, 2010.Notification of award will be made by June 1, 2010.Contact Rosa Lopez at roslopez@chla.usc.edu with any questions.
Cure Congenital Muscular Dystrophy Research Grants
Cure CMD Research Grant GoalsCure CMD research goals reflect our mission to bring research, treatments and in the future, a cure for the congenital muscular dystrophies. 1. Identify new therapeutic targets in the CMDs 2. Identify small molecule compounds that work at these therapeutic target sites with priority towards drugs with existing pediatric FDA approval 3. Facilitate the drug development process to ensure that each positive drug identification with promising preliminary data can be brought rapidly to preclinical trials and subsequent treatment trials 4. Support and endorse clinical research, infrastructure and biomarker discovery required to launch effective and efficient clinical trials in rare disease 5. Advance drug discovery with a diverse treatment pipeline 6. Support new scientific investigators with innovative ideas and a commitment to CMD researchStruggle Against Muscular Dystrophy (S.A.M) CMD Translational Research Grant: Annual Deadline, Sept 15th.
S.A.M is a unique CMD advocacy group launched by two parents whose son has CMD. SAM’s focus is to support and foster CMD research through successful fundraising initiatives. The SAM Translational Research Award delivers upon its promise to target research focused on CMD treatment. The grant is made possible through Cure CMD and SAM collaboration and the Cure CMD research grant funding mechanism.Cure CMD and SAM invite proposals to award a 1-2 year grant focusing on pre-clinical and clinical investigations that will advance treatment for congenital muscular dystrophy (CMD). The total award is limited to $100,000 (direct costs only). Annual RFA deadline Sept 15th. Grant application above. On the First Page of the Cure CMD grant application, please specify S.A.M. CMD Translational Research Grant
Cure CMD General Research Grants: Annual Deadline Sept 15th.
Elisabeth Giauque Short Term CMD Research Grant: Cure CMD provides a short-range or “seed” grant (usually $25,000- $50,000 per year for 1-2 years, direct costs only) to attract new investigators to the CMD field and assist existing investigators to support early phases of their research. The short-range grant focus is to collect preliminary data and test initial hypotheses. The short-range grant goal is to translate successful preliminary research to either second tier Cure CMD midrange grants (R-21 type) or third tier, long range (R-01 grants, 2-5 years) from outside funding sources, such as the National Institutes of Health. Annual RFA deadline, Sept 15th. Grant application above. On the first page of the Cure CMD grant application, please specify Elisabeth Giauque Short Term CMD Research Grant.
info@curecmd.comCure CMDP.O. Box 701Olathe, KS 66051Ph. 1-866-400-3626
American Speech-Language-Hearing Association 2010 Research Mentoring-Pair Travel Award
ASHA is pleased to announce the 2010 Research Mentoring-Pair Travel Award Program (RMPTA), given in conjunction with the 20th Annual NIDCD-Sponsored Research Symposium: Neural Plasticity: Mechanisms and Drivers of Functional Recovery in the Mature Brain, to be held in November 2010 at the annual ASHA Convention in Philadelphia, Pennsylvania.This award is designed to foster the professional development of students, clinicians, and emerging scientists who have expressed an interest in research careers in communication sciences and disorders. Up to 10 travel awards of $1,000 each will be granted to eligible mentor mentee pairs (mentee=$750; mentor=$250) to help defray the cost of attending the symposium.Special consideration will be given to individuals whose research or research interests are (a) relevant to the symposium topic, (b) interdisciplinary in nature, (c) translational in nature, or (d) related to issues of cultural or linguistic diversity.
EligibilityMentees must be (a) a current student at the master's, AuD, or PhD level, (b) a postdoctoral fellow, (c) a junior level faculty member (less than 6 years teaching/research experience in a tenure-track position or below the level of associate professor).Mentors must be a seasoned investigator in an academic or clinical research environment.
Application Packet ComponentsFive copies of the following will need to be submitted by the mentee in package: * Completed mentee application form * Curriculum vitae, resume or narrative biographical sketch detailing educational, clinical, and research experiences. * 1,000 word essay stating current research interests and activities, how attendance at this meeting could serve to enhance personal research career goals, and why this mentor mentee team is an appropriate match and will facilitate the goals of the mentee. * Mentoring plan outlining the mentor-mentee relationship both during and after the Symposium. * Letter of support from the mentor that acknowledges their agreement to the mentoring plan. * Completed mentor application form * Mentor's current curriculum vitaeDeadline for receipt of the completed application packet is Monday, June 21, 2010.Five collated copies of the Application Packet must be forwarded to:ASHA-RMPTA ApplicationJenise Cyrus2200 Research Blvd. #245Rockville, MD 20850-3289Please Note: If you intend to submit a proposal to the Convention Program, you must indicate that you are not able to present on Saturday, November 20, 2010.Still have questions? Contact Margaret Rogers, PhD, Chief Staff Officer for Science & Research at mrogers@asha.org.
American Society for Clinical Pharmacology and Therapeutics Young Investigator Award
ASCPT is now accepting applications for the 2010 Young Investigator Award (YIA). The YIA award is intended to support a fellow or junior faculty member in clinical pharmacology or related field. The award includes a $35,000 grant. Deadline for applications is May 13, 2010.
The Young Investigator award is intended to support a fellow or junior faculty member in clinical pharmacology or related field who is engaged in clinical/translational research.
ASCPT broadly defines clinical research to be investigation in clinical pharmacology that is hypothesis-driven research that is focused on drug discovery and molecular research, drug development, drug action and disposition, clinical trials, regulatory sciences, therapeutics and outcomes research. Our focus is on human-based research.
The applicant must have completed a doctoral degree (MD, PharmD or PhD) at the time of grant award (July 2010) and be in a fellowship program focused on clinical pharmacology or must be within one year of the anniversary date of their faculty appointment.
• An application will be made by the applicant that describes the applicant, mentor, institution, and project. The ASCPT selection committee will critically evaluate these applications.• An institutional commitment for a faculty appointment at time of grant submission is not required but the applicant should be working in a laboratory or clinical research setting.• The sponsoring facility must be an academic medical institution. The primary mentor must be in the candidate’s proposed research field, must assume responsibility, and provide guidance for the research.• Applicants must provide evidence that IRB approval is pending at the time of application.• If the mentor is not an active ASCPT member, a supporting letter from an ASCPT member must beincluded.• Applicants should be planning an investigative career in clinical pharmacology.• It is expected that at the time of the award, the applicant be a member of ASCPT.• The applicant should spend at least 60-75% of his or her time in research during the award period.• Eligible candidates may submit only one application to ASCPT per year.• The Grant is for a one-year period, July 1, 2010 - June 30, 2011, for the total amount of $35,000.
Payments are made to the applicant’s institution in two equal installments on July 1 and January 1. The grantis comprised of $31,000 to support the grant project, $1,500 for travel related to the project including theASCPT Annual Meeting and $2,500 for the institution to help defray the costs related to the administration ofthe project. Disbursement of funds is contingent upon final IRB approval. If final IRB approval if not given, the award will not be granted.
• The grant funds are directed to the sponsoring institution and may provide salary support, supplies, equipment, travel, etc. necessary for pursuit of the recipient’s research project.• At the conclusion of the grant period, a final report is required highlighting the project’s progress and summarizing the usage of funds.• In accordance with the goals of the ASCPT to assist with the careers of young investigators, recipients are required to respond to ASCPT’s requests for information on their career progress following the active grant.
The Young Investigator Award information can be downloaded from the ASCPT web site at www.ascpt.org
Questions about the Young Investigator Award can be directed to:Sharon J. Swan, CAE, ASCPT Executive DirectorSharon@ascpt.org or 703.836.6981
Applications are due to ASCPT by:5:00 pm Eastern time on Thursday, May 13, 2010Applications should be sent to:ASCPT, 528 North Washington Street, Alexandria, VA 22314 USA
Cytopathology Research Seed Grant
The ASC Foundation will grant $30,000 to a qualified young cytopathology professional (ASC Member) with no more than five years since completion of training, to conduct important research in cytopathology and attend the ASC Annual Scientific Meeting. The Grant will be presented every two years. Eligibility requires demonstration of commitment to ongoing research in cytopathology. The goal of this grant is to stimulate innovative translational research using material obtained from routine cytology specimens with the aim of improving the quality of work done by cytologists, thereby enhancing patient care. This includes (but is not limited to) application of new technologies to cytopathology.
1. The applicant must be an ASC Member in good standing. 2. A complete application, as specified in the instructions, must be submitted on the ASC Web site and received by September 1, 2010. 3. A curriculum vitae that includes educational training indicating the time, place and degrees awarded, and relevant awards and honors. 4. A statement of career goals (no more than one page) describing the applicant’s short- and long-term career goals and how the grant will enhance these career plans. The career statement should also include alternative means of support and activities that may be available should the applicant be unsuccessful in receiving the grant. 5. Letter of recommendation from two individuals or mentors who are familiar with the applicant’s potential. ** Research Grants should include information assuring that the mentor/sponsor has sufficient resources to facilitate the awardee and can support expenses beyond the awarded amount if the project incurs greater expenses. This letter should also include a statement that the mentor or applicant has an Internal Review Board approval for HIPAA compliant study of human samples, if applicable. 6. Letter from applicant explaining why he/she should be considered for the grant. 7. Application material should be submitted in the order listed. Pages should be numbered and submitted in page order.All applicants will be notified of the Foundation Board’s decision in October 2010. The grant awardees will be announced at the 58th Annual Scientific Meeting in Boston, Massachusetts.
ASC Foundation100 West 10th Street, Suite 605Wilmington, Delaware 19801(302) 543-6583awards@cytopathology.org
12next
